Korea United selected in Forbes Asia's "Best Under A Billion" list

Published: 2010-09-08 06:57:00

Updated: 2010-09-08 06:57:00

Korea United Pharmaceutical has continued to members of Forbes Asia's "Best Under A Billion" list for the second consecutive year, even as 151 new companies have made their maiden appearance on the list this year.

According to Fobes, Korea United Pharmaceutical's core offerings include antican...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK